Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic castration-resistant prostate cancer, drawn from the whole corpus: 121 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The best sequence of radioligand, PARP inhibitor and chemotherapy is untested.
Actinium-225 supply and the lack of alpha-emitter dosimetry.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Lineage plasticity to neuroendocrine disease under androgen receptor blockade.
Resistance to 177Lu-PSMA-617 in PSMA-low or FDG-discordant disease.
Background: Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA), Histologic transformation. Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 69 changes by month →When this page itself was last checked or edited.
Median overall survival 38.
PSMA+ mCRPC after ARPI, before chemotherapy (PSMAfore)
PSMA+ mCRPC after ARPI, before chemotherapy
rPFS significantly improved.
Median overall survival 24.